Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Alvotech

Request full access

Dedicated to broadening the availability and accessibility of biosimilars

Reykjavík, IcelandFounded 2013Biotech & Life Sciences

About Alvotech

Alvotech is a biopharmaceutical company that specializes in the development and manufacturing of biosimilars, which are essentially less expensive versions of biologic medicines. These medicines are used in the treatment of a variety of diseases, making Alvotech's work crucial in the healthcare sector. The company's primary goal is to improve lives by making biologic medicines more accessible and affordable.

Alvotech operates in the global pharmaceutical market, serving a wide range of clients, including healthcare providers and patients. The company's business model is vertically integrated, meaning it controls every stage of the process, from cell line development to the final stages of manufacturing. This approach allows Alvotech to maintain control, scale operations, and speed up the production process, thereby enhancing efficiency and cost-effectiveness.

The company generates revenue by selling its high-quality, cost-competitive biosimilars to healthcare providers worldwide. Alvotech also continually evaluates additional pipeline opportunities to expand its selection of biologic medicines, which could potentially lead to increased revenue streams.

Alvotech's recent financial results and business updates indicate positive growth and development, with the company announcing positive top-line results from a pharmacokinetic study for a proposed biosimilar. This suggests that Alvotech is not only maintaining its current operations but also actively pursuing new opportunities for growth and expansion.

In summary, Alvotech is a purpose-driven biopharmaceutical company that aims to improve lives by making biologic medicines more accessible and affordable.

Source: Dealroom company data

At a glance

Status
Listed
Listing
Public via SPAC 2021

Alvotech in the Reykjavík ecosystem

Live from Dealroom

The Alvotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

17 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Fuji Pharma

Series B and later16 investors entered at this stage

  • CVC Capital Partners
  • Sculptor
  • Suvretta Capital Management
  • Farallon Capital Management
  • Temasek
  • Arion banki
  • Landsbankinn
  • Athos
  • Arctica Finance
  • Oaktree Acquisition Corp. II
  • ATHOS Venture
  • Oaktree Capital Management
  • Lodbrok Capital
  • Morgan Stanley
  • Alvogen
  • GoldenTree Asset Management
Team profiled 21 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$2M

4 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Alvotech on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.